These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 19596991)
21. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474 [TBL] [Abstract][Full Text] [Related]
22. CD40 and its ligand in atherosclerosis. Lutgens E; Lievens D; Beckers L; Donners M; Daemen M Trends Cardiovasc Med; 2007 May; 17(4):118-23. PubMed ID: 17482093 [TBL] [Abstract][Full Text] [Related]
23. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. Müller D; Frey K; Kontermann RE J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif. He XH; Xu LH; Liu Y Acta Pharmacol Sin; 2006 Mar; 27(3):333-8. PubMed ID: 16490170 [TBL] [Abstract][Full Text] [Related]
25. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Gruss HJ; Duyster J; Herrmann F Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404 [TBL] [Abstract][Full Text] [Related]
26. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Zhou Z; Song X; Berezov A; Zhang G; Li Y; Zhang H; Murali R; Li B; Greene MI Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5465-70. PubMed ID: 18378892 [TBL] [Abstract][Full Text] [Related]
27. An isoleucine-zipper motif enhances costimulation of human soluble trimeric GITR ligand. Cui D; Wang S; Chen Y; Tong J; Ma J; Tang L; Yang X; Shi Y; Tian J; Lu L; Xu H Cell Mol Immunol; 2010 Jul; 7(4):316-22. PubMed ID: 20228835 [TBL] [Abstract][Full Text] [Related]
28. GITR/GITRL: more than an effector T cell co-stimulatory system. Nocentini G; Ronchetti S; Cuzzocrea S; Riccardi C Eur J Immunol; 2007 May; 37(5):1165-9. PubMed ID: 17407102 [TBL] [Abstract][Full Text] [Related]
29. Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Wieckowski S; Trouche N; Chaloin O; Guichard G; Fournel S; Hoebeke J Biochemistry; 2007 Mar; 46(11):3482-93. PubMed ID: 17319699 [TBL] [Abstract][Full Text] [Related]
30. Interaction of calreticulin with CD40 ligand, TRAIL and Fas ligand. Duus K; Pagh RT; Holmskov U; Højrup P; Skov S; Houen G Scand J Immunol; 2007 Nov; 66(5):501-7. PubMed ID: 17953526 [TBL] [Abstract][Full Text] [Related]
31. Small multivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. Trouche N; Wieckowski S; Sun W; Chaloin O; Hoebeke J; Fournel S; Guichard G J Am Chem Soc; 2007 Nov; 129(44):13480-92. PubMed ID: 17935324 [TBL] [Abstract][Full Text] [Related]
32. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. Robles-Carrillo L; Meyer T; Hatfield M; Desai H; Dávila M; Langer F; Amaya M; Garber E; Francis JL; Hsu YM; Amirkhosravi A J Immunol; 2010 Aug; 185(3):1577-83. PubMed ID: 20585032 [TBL] [Abstract][Full Text] [Related]
33. Modulation of acute and chronic inflammation of the lung by GITR and its ligand. Nocentini G; Cuzzocrea S; Bianchini R; Mazzon E; Riccardi C Ann N Y Acad Sci; 2007 Jun; 1107():380-91. PubMed ID: 17804566 [TBL] [Abstract][Full Text] [Related]
34. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality. Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216 [TBL] [Abstract][Full Text] [Related]
35. Oligomerization is required for the activity of recombinant soluble LOX-1. Cao W; Calabro V; Root A; Yan G; Lam K; Olland S; Sanford J; Robak A; Zollner R; Lu Z; Ait-Zahra M; Agostinelli R; Tchistiakova L; Gill D; Harnish D; Paulsen J; Shih HH FEBS J; 2009 Sep; 276(17):4909-20. PubMed ID: 19664054 [TBL] [Abstract][Full Text] [Related]
36. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Kober J; Leitner J; Klauser C; Woitek R; Majdic O; Stöckl J; Herndler-Brandstetter D; Grubeck-Loebenstein B; Reipert BM; Pickl WF; Pfistershammer K; Steinberger P Eur J Immunol; 2008 Oct; 38(10):2678-88. PubMed ID: 18825741 [TBL] [Abstract][Full Text] [Related]
37. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103 [TBL] [Abstract][Full Text] [Related]
38. Stoichiometry of LTbetaR binding to LIGHT. Eldredge J; Berkowitz S; Corin AF; Day ES; Hayes D; Meier W; Strauch K; Zafari M; Tadi M; Farrington GK Biochemistry; 2006 Aug; 45(33):10117-28. PubMed ID: 16906770 [TBL] [Abstract][Full Text] [Related]
39. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675 [TBL] [Abstract][Full Text] [Related]
40. Selective depletion of activated T cells: the CD40L-specific antibody experience. Hargreaves RE; Monk NJ; Jurcevic S Trends Mol Med; 2004 Mar; 10(3):130-5. PubMed ID: 15102356 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]